What is the share price of Sharon Bio-Medicine Ltd (SHARONBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sharon Bio-Medicine Ltd (SHARONBIO) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Sharon Bio-Medicine?

The latest standalone P/E ratio of Sharon Bio-Medicine as of 01-Jan-1970 is 0.10.

What is the P/B ratio of Sharon Bio-Medicine Ltd (SHARONBIO)?

The latest standalone P/B ratio of Sharon Bio-Medicine Ltd (SHARONBIO) as of 01-Jan-1970 is 0.00.

What is the 52-week high and low of Sharon Bio-Medicine Ltd (SHARONBIO)?

The 52-week high of Sharon Bio-Medicine Ltd (SHARONBIO) is Rs. 4.65 and the 52-week low is Rs. 3.10.

Sharon Bio-Medicine Ltd (SHARONBIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Sharon Bio-Medicine Ltd (SHARONBIO)
Brand: Sharon Bio-Medicine

Sharon Bio-Medicine Ltd (SHARONBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532908 NSE: SHARONBIO Pharmaceuticals & Drugs | Small Cap | Sharon Bio-Medicine Share Price

Sharon Bio-Medicine Ltd (SHARONBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532908 NSE: SHARONBIO Pharmaceuticals & Drugs | Small Cap | Sharon Bio-Medicine Share Price

Key Metrics

Valuation Multiples

Market Cap

₹2 Cr.

Current Price

₹0

52-Week Low / High

₹3 / 5

TTM EPS

₹33

TTM Sales

₹190 Cr.

Book Value per Share

₹-1,161.5

P/E Ratio

0.10

Industry PE

49.2

Price to Book (P/B)

0.00

Price to Sales (P/S)

0.01

EV/EBITDA

27.78

Dividend Yield

NAN%

Profitability Efficiency

Return on Equity (ROE)

58.92%

Return on Capital Employed (ROCE)

36.08%

Return on Assets (ROA)

19.68%

Operating Profit Margin

24.6%

Net Profit Margin

17.06%

Gross Profit Margin

25.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

21.76%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

35.82%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

76.92%

Asset Quality

Promoter Holding

0.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹-670 Cr.

Equity

₹1.2 Cr.

Face Value

₹2

All Time Low / High

₹2.60 / 90.20

Sharon Bio-Medicine stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	13.8%	14.7%	-12.8%	-27.7%	-77.2%	4.3%	9.8%	43.2%	25.2%	36.1%	-
Growth Parameters ⓘ
Sales ⓘ	1,060	1,314	834	338	139	188	192	190	197	240	190
Sales YoY Gr.	-	24%	-36.5%	-59.5%	-58.9%	35.7%	2%	-1%	3.8%	21.8%	-
Adj EPS ⓘ	5	6.6	-14.5	-27.9	-28.4	29.2	30.8	36,496.6	8,238.5	13,926.9	33
YoY Gr.	-	31.5%	-319.7%	NA	NA	NA	5.6%	118433.9%	-77.4%	69.1%	-
BVPS (₹) ⓘ	17.9	24.1	8	-22.9	-46.7	-1,130	-1,068.1	10,056.4	19,532.4	36,153.2	-1,161.5
Adj Net Profit ⓘ	52.9	69.6	-172	-332	-338	16.8	17.7	87.5	19.8	33.4	19
Cash Flow from Ops. ⓘ	-70.2	-69.5	-81.9	-37.6	33.9	23	41.1	66.9	38.2	45.1	-
Debt/CF from Ops. ⓘ	-9.2	-10.4	-10.1	-29.7	21.4	36	20.1	2.1	3.2	1.9	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-15.2%	11.6%	7.8%	21.8%
Adj EPS ⓘ	141.4%	NA	667.6%	69.1%
BVPSⓘ	133%	NA	NA	85.1%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	24.2	23.7	-74.6	786.2	91.8	-2.9	-2.9	-29.7	53.4	48	0.2
Op. Profit Mgn % ⓘ	11.4	12	-4.1	-52.8	-220.2	13.9	12.5	14.4	22.1	24.6	13.3
Net Profit Mgn % ⓘ	5	5.3	-20.7	-98.3	-243.7	8.9	9.2	46	10	13.9	10
Debt to Equity ⓘ	3.4	2.9	8.7	-4.1	-1.3	-1.3	-1.4	5.6	2.5	1	-
Working Cap Days ⓘ	198	202	322	761	586	164	190	154	150	148	161
Cash Conv. Cycle ⓘ	165	169	272	657	467	9	31	43	78	86	-160

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	1,059.50	1,313.77	833.95	253.45	138.81	188.39	192.22	190.23	197.48	240.45
Operating Expenses ⓘ +	939.01	1,156.71	868.34	387.29	444.48	162.19	168.20	162.80	153.87	181.22
Manufacturing Costs	10.74	12.43	19.47	14.11	12.48	28.63	24.68	39.63	37.94	46.52
Material Costs	902.08	1,112.75	808.50	332.25	237.40	84.44	92.90	71.18	67.77	85.35
Employee Cost	14.31	18.87	19.83	16.55	21.29	30.59	33.29	35.79	37.11	34.67
Other Costs ⓘ	11.88	12.66	20.55	24.39	173.32	18.52	17.33	16.19	11.04	14.68
Operating Profit ⓘ	120.49	157.06	-34.38	-133.84	-305.68	26.20	24.01	27.43	43.61	59.23
Operating Profit Margin (%)	11.4%	12.0%	-4.1%	-52.8%	-220.0%	13.9%	12.5%	14.4%	22.1%	24.6%
Other Income ⓘ +	0.89	1.68	2.63	1.95	19.85	2.81	4.46	63.98	7.76	11.50
Exceptional Items ⓘ	0	0	-76.64	-71.35	-13.70	0	0	0	0	0
Interest ⓘ	43.06	58.63	93.64	70.98	29.87	0.11	0.06	10.34	11.58	8.93
Depreciation ⓘ	12.13	15.35	19.17	15.01	16.12	11.23	9.40	9.70	8.77	7.85
Profit Before Tax ⓘ	66.19	84.75	-221.20	-289.24	-345.52	17.67	19.01	71.37	31.03	53.95
Tax ⓘ	13.33	15.14	4.66	9.97	2.34	0	0	-19.03	7.85	12.94
Profit After Tax	52.86	69.62	-225.86	-299.20	-347.86	17.67	19.01	90.40	23.18	41.01
PAT Margin (%)	5.0%	5.3%	-27.1%	-118.0%	-250.0%	9.4%	9.9%	47.5%	11.7%	17.1%
Adjusted EPS (₹)	5.0	6.6	-19.0	-25.2	-29.3	30.7	33.0	36,159.2	9,271.6	16,404.8
Dividend Payout Ratio (%)	3%	5.50%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Sharon Bio-Medicine - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	189.18	263.39	104.36	-195.21	-555.57	-609.22	-614.69	25.14	48.83	90.38
Share Capital ⓘ	10.56	21.11	23.79	23.79	23.79	1.15	1.15	0.01	0.01	0.01
Reserves ⓘ	178.62	242.27	80.57	-219	-579.36	-610.37	-615.84	25.14	48.83	90.38
Debt +	643.89	725.38	824.41	836.32	727.19	827.32	827.32	140.67	122.93	56.39
Long Term Debt	280.87	291.42	522.57	543.60	496.79	558.02	558.02	140.67	122.93	34
Short Term Debt	363.02	433.96	301.84	292.72	230.41	269.31	269.31	0	0	22.39
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	59.86	61.17	51.27	40.03	42.32	43.46	44.38	16.40	19.05	20.94
Others Liabilities ⓘ	79.01	111.69	31.48	41.70	139.66	37.57	33.96	2.43	11.41	46.84
Total Liabilities ⓘ	971.93	1,161.63	1,011.53	722.84	353.60	299.14	290.98	184.64	202.22	214.55
Fixed Assets
Net Fixed Assets ⓘ +	271.55	325.02	332.10	318.56	291.08	134.64	113.19	109.63	108.44	107.83
Gross Block	317.87	380.87	406.69	408.15	405.48	398.66	432.12	222.87	226.45	233.44
Accumulated Depreciation	46.33	55.85	74.58	89.60	114.40	264.02	318.93	113.24	118.01	125.61
CWIP ⓘ	42.82	14.93	0	0	0	0.15	0.20	1.80	1.51	0.23
Investments ⓘ	3.98	1.23	1.04	0.06	0	0	0	0	0	0
Inventories	260.24	322.45	301.42	179.99	21.03	42.33	39.02	25.43	35.43	41.33
Trade Receivables	355.10	414.31	315.02	183.18	21.62	26.88	26.09	27.95	40.11	51.14
Cash Equivalents	6.27	12.27	16.01	10.16	5.77	51.63	89.99	0.29	0.17	1.06
Others Assets ⓘ	31.98	71.41	45.94	30.90	14.10	43.51	22.48	19.53	16.57	12.97
Total Assets ⓘ	971.93	1,161.63	1,011.53	722.84	353.60	299.14	290.98	184.64	202.22	214.55

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	-70.23	-69.47	-81.91	-28.21	33.92	22.96	41.11	66.92	38.17	45.06
PBT ⓘ	66.19	84.75	-144.56	-217.89	-345.52	17.67	19.01	71.37	31.03	53.95
Adjustment ⓘ	41.92	59.20	31.96	4.04	219.21	10.13	8.44	-35.34	18.76	13.65
Changes in Working Capital ⓘ	-135.56	-154.8	124.34	256.62	189.77	-5.19	13.13	30.46	-11.82	-22.43
Tax Paid ⓘ	0	0	0	0	0.33	0	0.54	0.43	0.20	-0.11
Cash Flow From Investing Activity ⓘ +	-64.28	-27.38	-10.06	0.14	-1.38	-3.24	-2.77	-8.09	-8.99	1.05
Capex	-65.17	-31.81	-10.89	-1.47	-1.51	-4.51	-4.99	-8.99	-10.67	1.01
Net Investments	0	2.75	0.20	0.97	0	0	0	0	-0.06	0.02
Others ⓘ	0.89	1.68	0.63	0.64	0.12	1.26	2.21	0.90	1.74	0.01
Cash Flow From Financing Activity ⓘ +	134.50	102.85	95.70	22.22	-36.93	0.03	0.02	-148.53	-29.36	-45.18
Net Proceeds from Shares ⓘ	0	0	66.83	0	0	0	0	548.46	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	-417.35	-17.74	-58.93
Interest Paid ⓘ	0	0	0	0	-1.89	0	0	-10.33	-11.57	-8.64
Dividend Paid ⓘ	-1.58	-3.80	0	0	0	0	0	0	0	0
Others ⓘ	136.08	106.65	28.87	22.22	-35.03	0.03	0.02	-269.31	-0.05	22.39
Net Cash Flow ⓘ	-0.01	6	3.73	-5.85	-4.39	19.74	38.36	-89.70	-0.17	0.93

Financial Ratio

PARTICULARS	Jun'13	Jun'14	Jun'15	Mar'16	Mar'17	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	32.37	31.44	-129.46	N/A	N/A	N/A	N/A	0	62.67	58.92
ROCE (%)	13.76	14.73	-12.8	N/A	N/A	N/A	N/A	43.18	25.24	36.08
Asset Turnover Ratio	1.21	1.23	0.77	0.29	0.26	0.37	0.65	0.8	1.02	1.15
PAT to CFO Conversion(x)	-1.33	-1	N/A	N/A	N/A	1.3	2.16	0.74	1.65	1.1
Working Capital Days
Receivable Days	106	106.90	159.60	358.70	266.40	203.50	50.30	51.80	62.90	69.30
Inventory Days	78.60	80.90	136.50	346.60	261.50	215.40	77.20	61.80	56.20	58.30
Payable Days	22.20	19.90	25.40	50.20	63.30	180.50	172.60	155.80	95.50	85.50

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sharon Bio-Medicine Ltd FAQs

The current trading price of Sharon Bio-Medicine on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sharon Bio-Medicine stood at ₹1.85 Cr

The latest P/E ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.10.

The latest P/B ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.00.

The 52-week high of Sharon Bio-Medicine is ₹4.65 and the 52-week low is ₹3.10.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharon Bio-Medicine is ₹190 ( Cr.) .

Data is not available for this company.

The key valuation ratios of Sharon Bio-Medicine Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

No data found

About Sharon Bio-Medicine Ltd

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.

The companyâ€™s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.

It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.

Products

APIs and Pellets
Intermediates
Formulations

Milestones

1995 - The current management took over and started manufacturing of pharma intermediates
1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.

Sharon Bio-Medicine Ltd (SHARONBIO)

Sharon Bio-Medicine Ltd (SHARONBIO)

Sharon Bio-Medicine stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Sharon Bio-Medicine - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sharon Bio-Medicine Ltd FAQs

About Sharon Bio-Medicine Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Sharon Bio-Medicine Ltd (SHARONBIO)

Sharon Bio-Medicine Ltd (SHARONBIO)

Sharon Bio-Medicine stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Sharon Bio-Medicine - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sharon Bio-Medicine Ltd FAQs

What is the share price of Sharon Bio-Medicine?

What is the market cap of Sharon Bio-Medicine?

What is the P/E ratio of Sharon Bio-Medicine?

What is the P/B ratio of Sharon Bio-Medicine?

What is the 52-week high and low of Sharon Bio-Medicine?

What is the TTM revenue of Sharon Bio-Medicine?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Sharon Bio-Medicine Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.